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The patient perspective in the era of personalized medicine: 
What about scanxiety?
Frequency of scanning has accelerated in the era of per-
sonalized medicine and is related, but not restricted, to the 
exploding number of clinical trials for new cancer treat-
ments. Particularly in drug trials, but also in clinical prac-
tice, patients are followed up by scans frequently, which 
may vary from every 6 to 12 weeks until progression. The 
authors aimed to raise awareness for this underreported but 
widely present “Sword of Damocles” scan- related issue 
also referred to as ‘scanxiety.’
The term “scanxiety” was introduced in 2011 and defined as 
the anxiety and/or distress associated with an imaging test in 
postcancer follow- up, both ahead of the actual examination 
and up to the announcement of the test results.1 In oncology, 
scanxiety has been described in the context of imaging for 
assessment of potential metastatic disease in lung cancer2 or 
screening for recurrent disease in long- term lymphoma sur-
vivors.3 In these studies, scan- associated distress was most 
common in the days and weeks leading up to the examina-
tion, and presence of scanxiety was linked with significantly 
reduced quality of life.2 In the postcancer follow- up setting, 
imaging tests are scheduled on a regular basis one to four 
times a year, depending on the risk of cancer recurrence.
Frequency of scanning has accelerated in the era of per-
sonalized medicine and is related, but not restricted, to the 
exploding number of clinical trials for new cancer treat-
ments.4,5 Increased understanding of the genetic, molecular, 
and immunologic basis of cancer and the introduction of 
personalized medicines, has resulted in the development and 
introduction of diverse novel therapies and combinations of 
treatments that did not exist even 5 years ago. Many patients 
who would once have died within months will now live for 
years, but with cancer.6 Immune checkpoint inhibitors (ICI) 
were the first class of therapy shown to improve overall sur-
vival in patients with advanced melanoma; the anti- CTLA- 4, 
anti- PD- 1, and PDL- 1 antibodies are now part of the stan-
dard of care in everyday clinical practice. Moreover, combi-
nations of targeted agents add years of life to those affected 
by BRAF- mutated melanomas. Particularly in drug trials,4,5 
but also in clinical practice patients are followed up by scans 
frequently, which may vary from every 6 to 12 weeks until 
progression.7,8 However, frequent imaging evaluations of 
new potentially long- duration treatments may be distressing 
for cancer patients, because they typically feel very anxious 
and uncertain in the weeks before medical check- ups or con-
sultations, worrying about their medical status and the re-
sults. Afterwards, they emotionally process the information 
and results given in the consultation.9
The authors, including a patient, medical oncologist, ra-
diologist, and psychologists met together to raise awareness 
for this underreported but widely present scan- related issue in 
which recurrence or progression of disease continues to hang 
over patients and their families for the rest of their life like 
the sword of Damocles. As the patient representative quotes:
“In the weeks running up to the scan I begin to 
question every single ache and pain and worry 
that it might mean something. As well as this, 
the ludicrous number of irrational and often par-
anoid concerns begin to take over my head. So 
the pre- scan nerves are pretty terrifying but as 
scan day approaches the real fears kick in.”
The scans themselves cause anxiety as patients feel fright-
ened knowing someone is looking for progression. It is also hard 
to avoid seeking hidden meaning in the manner of the radiology 
staff wondering what they have seen on the scans. Despite the 
large numbers of scans which patients undergo, waiting for re-
sults gets harder with every scan because it is potentially even 
more life- changing/shortening than the last [Patient]. Therewith 
it is a realistic and justified fear related to possible progression, 
terminal disease, and being confronted with mortality. The 
issue of scanxiety should therefore not be addressed as anxiety 
disorder but relates to the concept of fear of cancer recurrence/
progression (FCR), a normal phenomenon for cancer patients. 
Only a small proportion develops clinical levels of FCR, char-
acterized by high levels of preoccupation, persistent high levels 
of worry and hypervigilance to bodily symptoms.10,11 Whether 
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scanxiety is a distinct feature of FCR, whether it leads to clini-
cal levels of FCR over time or how it is related to the concept of 
death anxiety12 is not yet understood.
This increase in scanning frequency and thus total num-
bers of scans per patient life might also put extra time pressure 
on radiologists. The Royal College of Radiologists workforce 
census revealed a 54% increase in CT scans and 48% increase 
in MRI scans between 2012 and 2017, which is not matched 
by an appropriate increase in workforce. As a consequence 8 
out of 10 English National Health Service (NHS) trusts have 
imaging studies unreported for 31 days or more.13 Patients 
trust that if there was anything to worry about, the alarm 
would be raised but it is possible that radiology review has 
not yet been undertaken.
“While we wait for results I almost lose the abil-
ity to speak, apparently I go a bit grey as those 
terribly terrifying but very possible scenarios go 
through my head. Strangely when I do get good 
results the feeling of relief is remarkably short- 
lived. I think it must be too complicated to be 
able to rejoice in being told that this time it’s all 
ok, this time, you’ve got away with it”.
After scan results, patients often have difficulties process-
ing what was talked about in the room with the doctor, and 
feelings of reassurance are not sustained. Literature shows that 
40– 80% of medical information provided by healthcare prac-
tioners is forgotten immediately, and that almost half of the in-
formation remembered is incorrect.14,15 Stress and anxiety can 
lead to attentional narrowing, limiting attentional resources for 
peripheral information which therefore cannot be recalled.16,17 
Furthermore, the concept of stable disease remains uncertain as 
it may mean both tending toward positive or negative results. 
Healthcare providers most times are aware of the limited recall 
of information conveyed during consultations and invest in re-
peated information provision.
The culmination of weeks of pre- scan nerves, waiting for 
results and processing of information result in a considerable 
time period dominated by scan -   related fear. Given scan re-
gimes of every 6 to 12 weeks, scanning puts a high burden on 
patients’ emotional functioning. This raises questions as to who 
benefits from short scanning intervals? The balance between 
information on disease status, emotional distress to patients 
and financial implications for over burdened healthcare sys-
tems must be given consideration. Scanning too early during 
therapy also increases the possibility of non- conclusive results 
which exacerbates anxiety related to uncertainty. For patients, 
increased scanning regimens seem to increase periods of dis-
tress. Life prolonging therapies should not only give a patient 
more days in life, but should also add life to the extra days. 
Furthermore, ICI trials use imaging protocols that result in high 
cumulative radiation exposure for patients. Before the ICI era, 
patients with advanced solid cancer had a very high chance of 
recurrence or progressive disease and did not live long enough 
to develop imaging -  induced secondary cancer. However, ICI 
improved the outcomes for a subgroup of patients resulting in 
increased number of long- term survivors, who have a higher 
risk to develop secondary cancer due to imaging radiation.5 For 
oncologists, a broader variety of patient- centered communica-
tion skills and instruments and allocated time for consultations 
are required. For society, healthcare costs are rapidly increasing 
and weighing the balance of continuation weeks of ineffective 
treatments with unnecessary potential side effects should be 
weighed against the costs and burden of frequent scans.
The results of novel therapies on overall survival are 
beneficial for some cancer patients with metastatic disease. 
However, the emotional cost related to medical advances 
and their development should also be acknowledged and ad-
dressed. Fears and hope in metastatic- cancer survivorship 
need attention. Defining the precise triggers and causes for 
scanxiety is an important first step in improving support for 
patients. For example, the impact of reducing time between 
scan and result findings should be assessed as a priority and 
could be a powerful influence on radiology workforce and 
workflow planning. Rationalizing the imaging schedule in 
discussion with patients may also alleviate anxieties. It is 
important to recognise that living with metastatic cancer 
is stressful and that patients may suffer from this the most 
outside the walls of the hospital and the immediate scope of 
their oncologists. Only by exploring with patients what they 
 prefer, can oncology care truly be personalized.
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